Advertisement


Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

2024 ASCO Annual Meeting

Advertisement

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
IMpower010, which looked at adjuvant atezolizumab for patients with completely resected early stage non-small cell lung cancer, we presented the long-term final disease-free survival as well as the second interim overall survival data, now with over 60 months of follow-up. The study had a complex hierarchical statistical design such that first group were those with PD-L1 expression stage 2 to 3A, next group, all stage 2 to 3A, then all comers, including about 12% of patients with 1B, and only if all three of those were met could we formally test overall survival. As was seen in the first interim analysis, the second interim now with the final disease-free survival in that first group with PD-L1 expression stage 2 to 3A remains robust with a hazard ratio of 0.7, translating into nearly a 30-month difference in disease-free survival. In the second group, when we look at all stage 2 to 3A, continue to see a disease-free survival benefit, which does reach statistical significance, hazard ratio of 0.85. But when we bring in that stage 1B, that drops to... Sorry, that was 0.83. ... 0.85, when we bring in that other group, no longer statistically significant. So overall survival could not be formally tested, but we do continue to see this robust disease-free survival benefit, particularly in those with PD-L1 expression. And when we look at those with the highest PD-L1 expression, greater than 50%, that disease-free survival benefit hazard ratio was 0.48. We haven't reached the median for that group of patients. And, in that group, the overall survival hazard ratio was 0.47. However, we can't formally statistically test that because of the way the trial is designed. So in conclusion, when we look at this final disease-free survival result and second interim overall survival result from IMpower010, we do continue to see robust clinical benefit for patients who have gone through surgical resection with early stage lung cancer, stage 2 to 3A, where their tumor expresses PD-L1 expression. And we do believe this continues to be a very reasonable treatment option for that subgroup of patients where there is PD-L1 expression, particularly in those with the highest PD-L1 expression of greater than 50%.

Related Videos

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Breast Cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Gastroesophageal Cancer

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Advertisement

Advertisement




Advertisement